Emgality (Galcanezumab-Gnlm) Drug Interactions: 1 Moderate
Emgality (Galcanezumab-Gnlm) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Emgality. Always confirm against the full prescribing information.
100 interactions
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Galcanezumab.
Level 2 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Aducanumab is combined with Galcanezumab.
Level 2 evidence
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galcanezumab.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Galcanezumab.
Level 2 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Galcanezumab is combined with Amivantamab.
Level 2 evidence
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Galcanezumab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Galcanezumab is combined with Ansuvimab.
Level 2 evidence
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Galcanezumab.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Galcanezumab.
Level 2 evidence
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Galcanezumab.
Level 2 evidence
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Galcanezumab.
Level 2 evidence
Atezolizumab
The risk or severity of adverse effects can be increased when Atezolizumab is combined with Galcanezumab.
Emgality (Galcanezumab-Gnlm) has 162 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Emgality (Galcanezumab-Gnlm) has 0 major, 1 moderate, and 161 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Emgality. Always confirm against the full prescribing information.